Helus Pharma welcomed the White House Executive Order aimed at accelerating research, regulatory pathways, and patient access to psychedelic treatments for serious mental health conditions. The executive order introduces several key initiatives including prioritization of FDA review for psychedelic therapies with Breakthrough Therapy designation, expanded access for eligible patients, increased federal funding to support state-level programs, and strengthened coordination among the Department of Health and Human Services, the FDA, and the Department of Veterans Affairs.
Helus Pharma’s lead program, HLP003, is currently in Phase 3 development and has received FDA Breakthrough Therapy designation for adjunctive treatment of major depressive disorder. The company is committed to developing proprietary novel serotonergic agonists—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity—to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Interim Chief Executive Officer Eric So emphasized that while policy momentum is meaningful, the future of the psychedelic field will ultimately be determined by the strength of clinical evidence and the ability to deliver safe, reliable treatments at scale. Helus Pharma believes the executive order will help advance novel treatment options for major depressive disorder and generalized anxiety disorder, where millions of patients continue to experience inadequate response to existing therapies.
The company is also developing HLP004, a proprietary novel serotonergic agonist in Phase 2 for generalized anxiety disorder, in addition to an extensive research portfolio of investigational novel serotonergic agonists. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/pressreleases/26/04/g51910128/helus-pharma-expresses-support-for-executive-order-advancing-psychedelic-research-and-regulatory-p